HIV/AIDS
New research on HIV/AIDS from S.A. Riddler and co-authors summarized
Published in AIDS Weekly, June 16th, 2008
"The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs," investigators in the United States report.
"In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-06-16)
More Articles from AIDS Weekly
- Johns Hopkins University Bloomberg School of Public Health
Extended infant antiretroviral prophylaxis reduces HIV risk during breastfeeding - HIV/AIDS
Findings from A. Sarna and co-authors provide new insights into HIV/AIDS - HIV/AIDS
Investigators at University of Bologna zero in on HIV/AIDS - HIV/AIDS
New HIV/AIDS study results reported from University of Medicine and Dentistry of New Jersey - HIV/AIDS
Recent studies from Trimeris, Inc. add new data to HIV/AIDS - HIV/AIDS
Researchers from Tor Vergata University discuss findings in HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
